Home Product listing Arcturus Therapeutics Reports Incentive Grant Under Nasdaq Listing Rule 5635 (c) (4)

Arcturus Therapeutics Reports Incentive Grant Under Nasdaq Listing Rule 5635 (c) (4)

4
0

SAN DIEGO, October 21, 2021– (BUSINESS WIRE) – Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA drug company focused on the development of vaccines against infectious diseases and Significant Opportunities in Liver and Rare Respiratory Diseases, today announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors have approved option incentive grants purchase of shares to purchase a total of 57,200 common shares of Arcturus from 5 newly hired employees, subject to the filing of a Form S-8 Registration Statement, which was filed today. The equity awards were granted in accordance with the incentive grant exception to Nasdaq rule 5635 (c) (4) as part of each individual’s compensation and were granted as an material incentive to accept a job with the Company.

The options have an exercise price equal to $ 46.98 per share, the closing price of the Company’s common shares as reported by the Nasdaq on October 15, 2021. The options have a ten-year term and vest on four years, with 25% of the number of shares underlying the vested stock options on the one year anniversary of the applicable vesting start date (based on the quarter in which the employee’s employment has started) and the remaining shares vest monthly for 36 months thereafter. Share awards are subject to the continued service of each person within the Company until the applicable vesting dates.

About Arcturus Therapeutics
Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA drug and vaccine company with enabling technologies: (i) LUNAR® lipid-mediated delivery , (ii) STARR ™ mRNA technology and (iii) mRNA drug substance as well as expertise in manufacturing pharmaceuticals. Arcturus’ diverse portfolio of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, as well as other programs to potentially treat ornithine transcarbamylase deficiency (OTC) and cystic fibrosis, as well as partner programs such as Glycogen. Type 3 storage disease, hepatitis B virus and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapy platforms can be applied to many types of nucleic acid drugs including messenger RNA, small interfering RNAs, replicon RNA, antisense RNA, microRNA , DNA and gene editing therapies. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications granted in the United States, Europe, Japan, China and other countries). Arcturus’ commitment to the development of new RNA-based therapies has led to collaborations with Janssen Pharmaceuticals, Inc., which is part of the pharmaceutical companies Janssen of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information, visit www.ArcturusRx.com. In addition, please contact us on Twitter and LinkedIn.

Forward-looking statements
This press release contains forward-looking statements that involve substantial risks and uncertainties for the safe harbor purposes of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included in this press release press, are forward-looking. statements, including those regarding strategy, future operations, collaborations, likelihood of success (including safety and effectiveness) of the Company’s pipeline, launch, design or planned completion of clinical trials , the likelihood of a patent being granted from any patent application, its current cash position and expected cash consumption as well as the impact of general business and economic conditions. Arcturus may not actually carry out plans, achieve intentions or meet expectations or projections disclosed in forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under “Risk Factors” in Arcturus’ annual report on Form 10-K for the year ended. December 31, 2020, and in subsequent filings with, or submissions to, the SEC. Unless otherwise provided by law, Arcturus disclaims any intention or obligation to update or revise forward-looking statements, which are only valid on the date on which they were made, whether as a result of new information, future events or circumstances or otherwise.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211020006142/en/

Contacts

Arcturus Therapeutics
Deepankar Roy, Ph.D.
(858) 900-2682
[email protected]

Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
[email protected]



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here